HOME > COMMENTARY

COMMENTARY

June 7, 2004
May 24, 2004
BULLETIN

May 24, 2004
Brand Equity in the Pharmaceutical Industry

March 8, 2004
＜Special Contribution＞ Breakthrough Candidates from Japanese Pharmaceutical Industry in 2004 (2)

March 8, 2004
March 1, 2004
Pursuing the Value of the Japanese Pharm Industry (2)

February 9, 2004
＜New Series＞ Pursuing the Value of the Japanese Pharm Industry (1)

January 19, 2004
＜Special Contribution＞ Happy New Year to Japanese Pharmaceutical Stocks!

January 12, 2004
＜Special Contribution＞ Global Products Enhance Dominance in Japan with Local Products Confined to Niche Markets

January 12, 2004
November 10, 2003
＜Special Contribution＞

November 3, 2003
＜Special Contribution＞

September 1, 2003
Forecasting the Hypertensives Market: A Look Five Years Ahead Sugio Seko　President, Pharma Marketing Survey Research Laboratory

August 11, 2003
June 9, 2003
May 12, 2003
March 24, 2003
January 20, 2003
< Special Contribution >

January 13, 2003
BARKER ON DRUGS

December 23, 2002

ページ

Chuikyo Debate on FY2026 Drug Pricing Reform

Chuikyo Backs Draft FY2026 Pricing Reform Outline, Rejects Key Industry Requests

By Takashi Ebisawa

The Ministry of Health, Labor and Welfare (MHLW) on December 12 presented a draft outline of the FY2026 drug pricing…

COLUMN

AI: Your New HR BFF (Not Your Replacement!)

By Philip Carrigan

Let’s ditch the stuffy jargon and talk about AI in HR like real humans.One of the biggest myths floating around is that AI is coming to steal our jobs. Newsflash: that’s not happening. Sure, AI can handle the boring stuff…

COMMENTARY

Radioligand Therapy Faces Capacity Bottleneck in Japan, System Build-Out Needed to Deliver on Promise

By Koji Shimomura

Novartis’ Pluvicto (lutetium vipivotide tetraxetan (177Lu)) won reimbursement listing in Japan in November as a radioligand therapy (RLT) for PSMA-positive…